Finance

Lists
Why is OCGN up 13,29%?
Dive Deeper
OCGN:NASDAQ
Ocugen Inc
USD 0,92
+13,29%
(+0,11) 1D
USD 0,93
+0,67% (+0,0062)
After hours
Closed: 6 Nov., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OCGN...
Open
USD 0,83
High
USD 0,97
Low
USD 0,82
Mkt. cap
312,34 m
Avg. vol.
6,79 m
Volume
7,47 m
52-wk high
USD 2,72
52-wk low
USD 0,69
EPS
-USD 0,25
Beta
2,04
Shares outstanding
339,31 m
No. of employees
116
Open
USD 0,83
High
USD 0,97
Low
USD 0,82
Mkt. cap
312,34 m
Avg. vol.
6,79 m
Volume
7,47 m
52-wk high
USD 2,72
52-wk low
USD 0,69
EPS
-USD 0,25
Beta
2,04
Shares outstanding
339,31 m
No. of employees
116
News stories
From web sources and news partners
About Ocugen Inc
CEOShankar Musunuri
Employees116
Founded2013
HeadquartersMalvern, Pennsilvanië, Verenigde State van Amerika
SectorHealth Care
Industry-
Websiteocugen.com
Analyst ratings
Based on 5 analysts giving stock ratings to OCGN in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for OCGN in the last 3 months.
Highest
Current USD 0,92
USD 12,00 (+1 197,30%)
Average
USD 10,20 (+1 002,70%)
Lowest
USD 8,00 (+764,86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Maintained
USD 11,00
+1 089,2%
11/04/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
USD 10,00
+981,1%
11/05/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
USD 10,00
+981,1%
09/29/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
USD 12,00
+1 197,3%
09/28/2026
Michael Okunewitch
Maxim Group
Buy
Reiterated
USD 8,00
+764,9%
09/16/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
USD 7,00
+656,8%
05/07/2026
Elemer Piros
Lucid Capital
Buy
Maintained
USD 22,00
+2 278,4%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
-193,00 k
1,53 m
1,49 m
1,95 m
Cost of goods sold
10,67 m
11,26 m
10,69 m
12,50 m
Cost of revenue
10,67 m
11,26 m
10,69 m
12,50 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,13 m
8,12 m
7,24 m
7,20 m
Operating expense
6,13 m
8,12 m
7,24 m
7,20 m
Total operating expenses
16,80 m
19,37 m
17,93 m
19,70 m
Operating income
-17,00 m
-17,84 m
-16,44 m
-17,75 m
Other non operating income
477,00 k
-150,00 k
-1,97 m
16,60 m
EBT including unusual items
-17,71 m
-19,18 m
-24,88 m
-3,60 m
EBT excluding unusual items
-17,71 m
-19,18 m
-22,49 m
-3,60 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17,71 m
-19,18 m
-24,88 m
-3,60 m
Net profit margin
9 174,09%
-1 250,95%
-1 671,84%
-184,42%
Earnings per share
-0,06
-0,06
-0,06
-0,06
Interest and investment income
144,00 k
132,00 k
395,00 k
649,00 k
Interest expense
-1,33 m
-1,32 m
-4,48 m
-3,09 m
Net interest expenses
-1,19 m
-1,19 m
-4,08 m
-2,44 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-16,40 m
-17,25 m
-15,86 m
-17,17 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme